Literature DB >> 29204962

Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease.

Luisa Chiapparini1, Giulio Cavalli2, Tiziana Langella3, Anna Venerando4, Giacomo De Luca2, Sergio Raspante5,6, Giorgio Marotta7, Bianca Pollo8, Giuseppe Lauria9,10, Maria Giulia Cangi11, Simonetta Gerevini12, Andrea Botturi13, Davide Pareyson14, Lorenzo Dagna2, Ettore Salsano14.   

Abstract

BACKGROUND: Leukoencephalopathies with prominent involvement of cerebellum and brainstem, henceforward called prominent infratentorial leukoencephalopathies (PILs), encompass a variety of inherited and acquired white matter diseases. Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis likely under-diagnosed as cause of adult PIL.
METHODS: We reviewed the clinical and laboratory information of ten consecutive sporadic adult patients with PIL of unknown origin, who were investigated for ECD.
RESULTS: There were seven males and three females; mean age at clinical onset was 49.6 years (range 38-59); cerebellar ataxia with or without other neurological symptoms was the only or the main clinical manifestation; diabetes insipidus was present in three individuals. Eight patients had white matter focal supratentorial abnormalities, in addition to the infratentorial white matter changes. Six out of eight patients had spinal cord lesions. Thoraco-abdominal CT showed periaortic sheathing in two patients, whole-body FDG-PET revealed increased glucose uptake in the long bones of the legs in five patients, brain FDG-PET showed overt infratentorial hypermetabolism in one patient. In eight patients, ECD was confirmed by bone scintigraphy, pathological data, or both. Two ECD patients treated with vemurafenib showed a marked improvement of neurological symptoms and brain MRI abnormalities at 1 year follow-up.
CONCLUSIONS: Symptoms of PIL can be the only clinical manifestation of ECD. Adult patients with PIL of unknown origin should undergo investigations aimed at unveiling ECD, including bone scintigraphy and whole-body FDG-PET. The early diagnosis allows starting disease-modifying therapies of an otherwise life-threatening disease.

Entities:  

Keywords:  Erdheim–Chester disease; Histiocytosis; Imaging; Leukodystrophy; Leukoencephalopathy; White matter lesion

Mesh:

Substances:

Year:  2017        PMID: 29204962     DOI: 10.1007/s00415-017-8692-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease.

Authors:  P Sedrak; L Ketonen; P Hou; N Guha-Thakurta; M D Williams; R Kurzrock; J M Debnam
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-29       Impact factor: 3.825

2.  18F-FDG PET/CT in Erdheim-Chester disease.

Authors:  Rosa Fernández López; Irene Acevedo Báñez; Manuel Beltrán Robles; Isabel Borrego Dorado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-31       Impact factor: 9.236

3.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 4.  Posterior fossa involvement in the diagnosis of adult-onset inherited leukoencephalopathies.

Authors:  Xavier Ayrignac; Clemence Boutiere; Clarisse Carra-Dalliere; Pierre Labauge
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

Review 5.  MR imaging of the brain in patients with diabetes insipidus.

Authors:  R Tien; J Kucharczyk; W Kucharczyk
Journal:  AJNR Am J Neuroradiol       Date:  1991 May-Jun       Impact factor: 3.825

6.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

Review 7.  Erdheim-Chester disease.

Authors:  Corrado Campochiaro; Alessandro Tomelleri; Giulio Cavalli; Alvise Berti; Lorenzo Dagna
Journal:  Eur J Intern Med       Date:  2015-04-10       Impact factor: 4.487

8.  Central diabetes insipidus: Is it Langerhans cell histiocytosis of the pituitary stalk? A diagnostic pitfall.

Authors:  Helmut Prosch; Nicole Grois; Jos Bökkerink; Daniela Prayer; Ivo Leuschner; Milen Minkov; Helmut Gadner
Journal:  Pediatr Blood Cancer       Date:  2006-03       Impact factor: 3.167

9.  Invited article: an MRI-based approach to the diagnosis of white matter disorders.

Authors:  Raphael Schiffmann; Marjo S van der Knaap
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

Review 10.  Brainstem glioma: a review.

Authors:  Sean A Grimm; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

View more
  3 in total

1.  Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.

Authors:  Ankush Bhatia; Vaios Hatzoglou; Gary Ulaner; Raajit Rampal; David M Hyman; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Mariko Yabe; Kseniya Petrova-Drus; Katherine S Panageas; Anne Reiner; Marc Rosenblum; Eli L Diamond
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

2.  Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.

Authors:  Alessandro Tomelleri; Giulio Cavalli; Giacomo De Luca; Corrado Campochiaro; Teresa D'Aliberti; Moreno Tresoldi; Lorenzo Dagna
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

Review 3.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.